Luteolin reduced tau hyperphosphorylation at S262 and S356 via control of the phosphorylation/dephosphorylation system and its antioxidant activity.[128] In an AD mouse model employing streptozotocin, luteolin‐loaded chitosan decorated nanoparticles demonstrated anti‐inflammatory and antioxidant properties and inhibited tau hyperphosphorylation and Aβ aggregates formation.[129] Moreover, luteolin's activity as an acetylcholinesterase inhibitor, among other properties, indicates its therapeutic potential in treating AD.[130, 131]. Here, MAPT is linked to Alzheimer disease.